|
Alden Ladd
Associate Director of Cell Process Development
Miltenyi Biotec B.V. & Co. KG
Cambridge
USA
|
Alden Ladd is currently an Associate Direct of Immune Cell Process Development at Beam Therapeutics. He received his BS in Biochemistry from Northeastern University in 2013. He began his career at Bluebird Bio where he helped to develop idecabtagene vicleucel (Ide-Cel) for treatment of Multiple Myeloma from concept through pre-BLA filing. During his time at Bluebird bio he was heavily involved in CMC, analytical development, and technology transfer activities as well as the early stage development of several novel CAR-T therapies for liquid and solid tumors. In 2020 he joined Beam Therapeutics where he helped to develop the multiplex base edited allogeneic CAR-T therapy Beam-201 for the treatment of Acute Lymphoblastic Leukemia, the IND for which was recently approved. Since joining Beam he has transferred into his now role as Associate Director of Immune Cell Process Development and leads a team working on emerging tumor targets and modalities.